


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 257/04, 249/12, 271/10, 401/10, 405/10, 409/10, A61K 31/41		A1	(11) International Publication Number: WO 98/47879
			(43) International Publication Date: 29 October 1998 (29.10.98)
(21) International Application Number: PCT/DK98/00162		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG; ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 April 1998 (21.04.98)			
(30) Priority Data: 0452/97 22 April 1997 (22.04.97) DK			
(71) Applicant (for all designated States except US): NEUROSEARCH A/S [DK/DK]; Smedeland 26 B, DK-2600 Glostrup (DK).			
(72) Inventors; and (75) Inventors/Applicants (for US only): CHRISTOPHERSEN, Palle [DK/DK]; NeuroSearch a/s, Smedeland 26 B, DK-2600 Glostrup (DK). PEDERSEN, Ove [DK/DK]; NeuroSearch a/s, Smedeland 26 B, DK-2600 Glostrup (DK).			
(74) Common Representative: NEUROSEARCH A/S; Smedeland 26 B, DK-2600 Glostrup (DK).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Substituted phenyl derivatives, their preparation and use

The present invention relates to novel substituted phenyl derivatives which are potent chloride channel blockers and as such useful in the treatment of sickle cell anaemia, brain oedema following ischaemia or tumours, diarrhoea, hypertension (diuretic),
5 osteoporosis, and for the reduction of the intraocular pressure for the treatment of disorders such as glaucoma.

Background

10

Chloride channels serve a wide variety of specific cellular functions. Thus, chloride channels contribute to the normal function of skeletal and smooth muscle cells. Blockers of chloride channels are known to be useful in the treatment of brain oedema following ischaemia or tumours, diarrhoea, hypertension (diuretic), osteoporosis and
15 for the reduction of the intraocular pressure in disorders such as glaucoma. The compounds of the invention may also be useful in the treatment of allergic and inflammatory conditions and for the promotion of wound healing.

The use of blockers of chloride channels for the treatment sickle-cell anaemia form a
20 new therapeutic approach.

Sickle cell anaemia and the existence of sickle haemoglobin was the first genetic disease to be understood at the molecular level. The genetic defect underlying sickle cell anaemia causes the substitution of a single amino acid resulting in a mutant
25 haemoglobin, sickle haemoglobin.

The physical manifestations of sickle cell disease is anaemia and painful ischaemic crises due to occlusion of the microcirculation by deformed erythrocytes (sickle cells). The primary cause of sickle erythrocyte deformation and distortion (or sickling) is a
30 reversible polymerisation and gelation of sickle haemoglobin induced at the low oxygen tensions prevalent in metabolically active tissues. Sickle cells are also characterised by an enhanced cation permeability, resulting in cation depletion and cellular dehydration. Since the delay time for the polymerisation has been described

as an extremely steep function of the sickle haemoglobin concentration itself, any decrease in cell volume will greatly increase the probability of sickling and thereby of vessel occlusion. Compounds which blocks the deoxygenation induced salt and volume (water) loss may delay the sickling process enough to avoid occlusion upon
5 the passage of the sickle erythrocyte through metabolically active tissue. It has been estimated that a delay time of only 10 sec may suffice.

Several membrane ion channels and transporters present in normal erythrocytes has been suggested to participate in the altered membrane permeabilities of sickle cells.
10 The favoured hypothesis has been stimulation of the Ca^{2+} -activated K^{+} -channel and several blockers of this channel has been suggested as therapeutic agents for the treatment of sickle-cell anaemia (Effects of Cetiedil on Monovalent Cation Permeability in the Erythrocyte: An explanation for the Efficacy of Cetiedil in the treatment of Sickle Cell Anaemia, Berkowitz, L. R., Orringer, E. P., Blood cells, (283-
15 288 (1982) and US patent No. 5.273.992).

Since, K^{+} efflux through a K-channel must be followed by an equal efflux of Cl^{-} to maintain electroneutrality, blockade of erythrocyte chloride channels should be as effective as blocking the K-channels itself. An advantage to the use of chloride channel blockers is that salt loss which may occur due to activation of unknown
20 K-channel types will indirectly be blocked too.

The compounds of the present invention are potent blockers of chloride channels as measured by concomitant measurements of conductive netfluxes of chloride and membrane potentials in suspensions of erythrocytes, and the compounds are
25 therefore predicted to be useful in the treatment of sickle-cell disease.

Several chloride channel blockers and the use thereof have already been described:

Pflügers Arch (1986), 407 (suppl. 2), pages 128-141 describes several compounds
30 with chloride channel blocking activity. A very potent compound described herein is 5-nitro-2-(3-phenylpropylamino)benzoic acid. The use of chloride channel blockers for the treatment of sickle cell anaemia is not disclosed herein.

US patent No. 4.889.612 describes Calixarene derivatives and their use as chloride channel blockers.

US patent No. 4.994.493 describes certain 5-nitrobenzoic acid derivatives and their
5 use in the treatment of cerebral oedema.

WO 96/16647 describes the use of chloride channel blockers for reduction of the intraocular pressure and specifically the use of chloride channel blockers for the treatment of glaucoma.

10

The present invention relates to a series of substituted phenyl derivatives which are potent chloride channel blockers, and their use in the treatment of sickle-cell anaemia, for example.

15

Objects of the Invention

It is an object of the present invention to provide novel substituted phenyl derivatives and pharmaceutically acceptable salts thereof which are useful in the treatment of disorders or diseases responsive to the blockade of chloride channels.

20


Still another object of the present invention is to provide a method of treating disorders or diseases responsive to the blockade of chloride channels, such as for example brain oedema following ischaemia or tumours, diarrhoea, hypertension (diuretic), osteoporosis, glaucoma and in particular sickle-cell anaemia.

25

Summary of the Invention

The invention then comprises, inter alia, alone or in combination:

30 A compound having the formula



or a pharmaceutically acceptable salt thereof

- 5 wherein one of R^1 , R^2 and R^3 is a cyclic or heterocyclic acidic functional group having a pK_a value below 8 or a group which is convertible in vivo to such a group;

- R^4 , R^5 and the two other substituents R^1 , R^2 and R^3 are each independently selected from hydrogen; alkyl; alkoxy; hydroxy; halogen; trifluoromethyl; cyano; nitro; amino; alkylamino; $-COOR^7$; $-NHSO_2$ -alkyl; $-SO_2N(R^7)_2$; $-SO_2OR^7$; $-CO-R^7$; aryl, biphenyl, phenylamino, phenoxy or heteroaryl, wherein the aryl, biphenyl, phenylamino, phenoxy or heteroaryl group may be substituted one or more times with substituents selected from alkyl, hydroxy, alkoxy, halogen, trifluoromethyl, cyano, nitro, amino and alkylamino; aryl and heteroaryl, or R^3 and R^4 or R^4 and R^5 together form a cyclic structure and the other substituents R^1 , R^2 , R^3 , R^4 and R^5 is as defined above;

and R^7 is hydrogen, alkyl, amino or phenyl;

Y is $-CO-$, $-CS-$, $-SO_2-$, or $-C(=N-R^8)-$, wherein R^8 is hydrogen, alkyl, or cyano;

X is $-NH-$, $-CH_2NH-$, or $-SO_2NH-$;

Z is NR^6 , O, $-CH=CH-$, $-N=CH-$, or $-CH=N-$

- 25 R^6 is hydrogen, or alkyl;

- R^{11} , R^{12} , R^{13} , R^{14} and R^{15} are each independently selected from hydrogen; alkyl; alkoxy; hydroxy; halogen; trifluoromethyl; cyano; nitro; amino; alkylamino; $-COOR^7$; $-NHSO_2$ -alkyl; $-SO_2N(R^7)_2$; $-SO_2OR^7$; $-CO-R^7$; aryl, biphenyl, phenylamino, phenoxy or heteroaryl, wherein the aryl, biphenyl, phenylamino, phenoxy or heteroaryl group may

be substituted one or more times with substituents selected from alkyl, hydroxy, alkoxy, halogen, trifluoromethyl, cyano, nitro, amino and alkylamino; aryl and heteroaryl, or one of R^{11} and R^{12} , R^{12} and R^{13} , R^{13} and R^{14} and R^{14} and R^{15} together form a cyclic structure and the other substituents R^{11} , R^{12} , R^{13} , R^{14} and R^{15} is as defined above and
 5 R^7 is as defined above;

a compound as above wherein one of R^1 , R^2 and R^3 is 3-hydroxy-4-oxo-pyranlyl, 2-hydroxy-4-oxo-pyrimidyl, 4-hydroxy-1,2,4-triazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 2,4-dioxo-imidazolidinyl, 2,5-dioxo-3-hydroxy-pyrrolyl, 2,5-dioxo-pyrrolidinyl, 2,4-dioxo-
 10 1,3-thiazolidinyl, 3-hydroxy-isoxazolyl, 5-hydroxy-isoxazolyl, 3-hydroxy-isothiazolyl, 3-hydroxy-1,2,5-thiadiazolyl, tetrazolyl, 3-hydroxy-triazolyl, 3-hydroxy-pyrazolyl, 2-hydroxy-1,3,4-oxadiazolyl or 2-hydroxy-3,4-dioxo-cyclobutenyl, 3-oxo-1,2-dihydro-1,2,4-triazolyl, 2-oxo-3H-1,3,4-oxadiazolyl, 3-oxo-1,2-dihydro-1,2,4-triazolyl; Z is NR^6 and Y is CO;

15

a compound as above, said compound being:

- 3-Trifluoromethylphenyl-4-nitro-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(2-naphthyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-pyridyl)-2-(5-tetrazolyl)phenyl urea;
- 20 3-Trifluoromethylphenyl-4-(1-naphthyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-trifluoromethylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-furyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-thienyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-nitrophenyl)-2-(5-tetrazolyl)phenyl urea;
- 25 3-Trifluoromethylphenyl-4-(4-ethoxycarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-diethylaminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-aminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-2-(4-hydroxy-1,2,4-triazol-3-yl)phenyl urea;
- 3-Trifluoromethylphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl urea;
- 30 3-Trifluoromethylphenyl-2-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl urea;
- 3-Trifluoromethylphenyl-4-biphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl urea;
- 3-Trifluoromethylphenyl-4-amino-2-(5-tetrazolyl)phenyl urea;

- 3-Trifluoromethylphenyl-4-acetylamino-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-benzoylamino-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-(4-carboxyphenyl)-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-(4-anilino-carbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
5 4-Biphenyl-2-(5-tetrazolyl)phenyl urea;
3-Biphenyl-2-(5-tetrazolyl)phenyl urea;
5-Indanyl-2-(5-tetrazolyl)phenyl urea;
3-Bromophenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.
3-Acetylphenyl-2-(5-tetrazolyl)phenyl urea.
10 3-Biphenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.
3-(3-Pyridyl)phenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.

a pharmaceutical composition comprising a therapeutically effective amount of a compound as any above or a pharmaceutically acceptable salt thereof together with
15 at least one pharmaceutically acceptable carrier or diluent;

the use of a compound as above for the preparation of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels;
20

the use of a compound as above for the preparation of a medicament for the treatment of sickle-cell anaemia, brain oedema following ischaemia, or tumours, diarrhoea, hypertension (diuretic), osteoporosis, glaucoma, allergic or inflammatory conditions or healing ulcers;
25


a method for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to such a living animal body in need thereof a therapeutically effective amount of a compound as above;
30

a method for the treatment of a disorder or disease of a living animal body which disorder or disease is sickle-cell anaemia, brain oedema following ischaemia or tumours, diarrhoea, hypertension (diuretic), osteoporosis, glaucoma, allergic or

inflammatory conditions or ulcers, comprising administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as any above;


5 a method for the preparation of a compound as above, comprising:

a) reacting a compound having the formula



10


wherein W is O, or S and R^{11} , R^{12} , R^{13} , R^{14} and R^{15} is as defined above, with a compound having the formula



15


wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 is as defined above, or

b) reacting a compound having the formula



20

wherein X, Y, R^6 , R^{11} , R^{12} , R^{13} , R^{14} and R^{15} is as defined above, with a compound having the formula



wherein Hal is halogen and R¹, R², R³, R⁴ and R⁵ is as defined above,

5

whereafter optionally the compound obtained is converted to another compound of the invention and/or a pharmaceutically acceptable salt thereof is formed using conventional methods; and

10 the use of chloride channel blockers in the treatment of sickle-cell disease.

Examples of pharmaceutically acceptable addition salts of the compounds of the invention include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2-sulphonate, salicylate and the acetate. Such salts are formed by procedures well known in the art.

20 Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.

Halogen is fluorine, chlorine, bromine or iodine.

25

Alkyl means a straight chain or branched chain of one to six carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl; methyl, ethyl, propyl and isopropyl are preferred groups.

30 Alkoxy is O-alkyl, wherein alkyl is as defined above.

Amino is NH_2 or NH-alkyl or N-(alkyl)_2 , wherein alkyl is as defined above.

The cyclic or heterocyclic acidic group having a pK_a below 8 or a group which is
5 converted in vivo to such group are groups such as 3-hydroxy-4-oxo-pyran-2-yl, 2-hydroxy-4-oxo-pyrimidin-2-yl, 3,5-dioxo-1,2,4-oxadiazolidin-2-yl, 2,4-dioxo-imidazolidin-2-yl, 2,5-dioxo-3-hydroxy-pyrrolyl, 2,5-dioxo-pyrrolidin-2-yl, 2,4-dioxo-1,3-thiazolidin-2-yl, 3-hydroxy-isoxazol-5-yl, 5-hydroxy-isoxazol-3-yl, 3-hydroxy-isothiazol-3-yl, 3-hydroxy-1,2,5-thiadiazol-3-yl, tetrazol-5-yl, 3-hydroxy-triazol-5-yl, 3-hydroxy-pyrazol-5-yl, 2-hydroxy-1,3,4-oxadiazol-5-yl, 4-
10 hydroxy-1,2,4-triazol-5-yl, 3-oxo-1,2-dihydro-1,2,4-triazol-5-yl, 2-oxo-3H-1,3,4-oxadiazol-5-yl, 3-oxo-1,2-dihydro-1,2,4-triazol-5-yl and 2-hydroxy-3,4-dioxo-cyclobutenyl.

Heteroaryl is a 5- or 6-membered heterocyclic monocyclic group. Such a monocyclic heteroaryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-
15 3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl, 1,2,5-thiadiazol-3-yl, 1,2,5-thiadiazol-4-yl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-
20 pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 1-pyrazolyl, 3-pyrazolyl, and 4-pyrazolyl, 2-furyl, 3-furyl, 4-furyl, 5-furyl.

Aryl is an aromatic hydrocarbon, such as phenyl or naphthyl.

25 The compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

30 It will be appreciated by those skilled in the art that the compounds of the present invention contain several chiral centres and that such compounds exist in the form of isomers (i.e. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Some of the compounds of the present invention exist in (+) and (-) forms as well as in racemic forms. Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example. The compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.

Additional methods for the resolution of optical isomers, known to those skilled in the art may be used, and will be apparent to the average worker skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

The compounds of the invention may be prepared in numerous ways. The compounds of the invention and their pharmaceutically acceptable derivatives may thus be prepared by any method known in the art for the preparation of compounds of analogous structure, and as shown in the representative examples which follow.

Biology

The compounds of the present invention are potent blockers of chloride channels in normal as well as sickle cell erythrocytes. The ability of the compounds to block the erythrocyte chloride channels can not be demonstrated by classical electrophysiological measurements such as patch clamping, since the channel unit conductance is below the detection limit of these techniques.

All dose-response experiments were therefore performed by concomitant measurements of conductive netfluxes of Cl^- (J_{Cl}) and membrane potentials (V_m) in suspensions of erythrocytes (Bennekou, P. and Christophersen, P. (1986), Flux ratio of Valinomycin - Mediated K^+ Fluxes across the Human Red Cell Membrane in the presence of the Protonophore CCCP. J. Membrane Biol. 93, 221-227.).

The membrane Cl^- conductances (G_{Cl}) were calculated by the following equation (Hodgkin, A. L. and Huxley, A.F. (1952) The components of membrane conductance in the giant axon of Loligo. J. Physiol. Lond. 116, 449-472):

$$G_{\text{Cl}} = \frac{F \cdot J_{\text{Cl}}}{(V_m - E_{\text{Cl}})}$$

where F is the Faraday constant, E_{Cl} is the Nernst potential for the Cl^- -ion.

Administration of 3-Trifluoromethylphenyl-2-carboxyphenyl urea to a suspension of normal erythrocytes blocked G_{Cl} more than 95 % with a K_D -value of 1.3 μM . The compound equipotently blocked G_{Cl} from oxygenated as well as deoxygenated homozygoteous sickle cell erythrocytes.

The K_D -value for 3-Trifluoromethyl-4-bromo-2-(5-tetrazolyl)-phenylurea in this test was 1.9 μM .

Experimentally induced cell volume losses were measured as changes in the relative volume of packed cells. Inducing a massive water and salt loss (KCl) by addition the K^+ -ionophore valinomycin to the suspension for 5 min reduced the cell volume by 26 %. 3-Trifluoromethylphenyl-2-carboxyphenyl urea dose-dependently (IC_{50} -value of 1.2 μM) reduced the volume loss to 7 %.

Deoxygenation induced permeability increases of sickle cells were estimated by measuring the extracellular K^+ -concentration vs time. Normal erythrocytes exhibited very small K^+ -fluxes, which was insensitive to deoxygenation and insensitive to 10 μM 3-Trifluoromethylphenyl-2-carboxyphenyl urea. The K^+ flux from oxygenated sickle

erythrocytes was 2-3 times higher than from normal erythrocytes and these fluxes was accelerated 4 - 8 times upon deoxygenation. In presence of 3-Trifluoromethylphenyl-2-carboxyphenyl urea (10 μ M) the basal K^+ -flux from sickle erythrocytes was normalised and the deoxygenation induced flux component were
5 nearly abolished.

3-Trifluoromethylphenyl-2-carboxyphenyl urea is non-toxic to mice and rats at concentrations up to 250 mg/kg i.p. and i.v.

10

Pharmaceutical compositions

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

15

The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be
20 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-
25 cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.

The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit
30 dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including

subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended
5 daily dosage range to be employed. Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.

The compounds of the present invention can be administrated in a wide variety of oral
10 and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present
15 invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

20

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding
25 capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth,
30 methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in

association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

- 5 For preparing suppositories, a low melting wax, such as admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed ... homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- 10 Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Liquid form preparations include solutions, suspensions, and emulsions, for example,
15 water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous
20 infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in
25 powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active
30 component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

5

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and
10 natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.

Ointments and creams may, for example, be formulated with an aqueous or oily base
15 with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

20 Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

25

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume
30 of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.

In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

When desired, formulations adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

Methods of treating

The compounds of the present invention are very useful in the treatment of sickle cell anaemia, brain oedema following ischaemia or tumours, diarrhoea, hypertension
5 (diuretic), osteoporosis and glaucoma, due to their potent chloride channel blocking activity. These properties make the compounds of this invention extremely useful in the treatment of sickle cell anaemia, brain oedema following ischaemia or tumours, diarrhoea, hypertension (diuretic), osteoporosis and glaucoma, as well as other disorders sensitive to the peripheral chloride channel blocking activity of the
10 compounds of the present invention. The compounds of this invention may accordingly be administered to a living animal body, including a human, in need of treatment, alleviation, or elimination of an indication associated with or responsive to chloride channel blocking activity. This includes especially sickle cell anaemia, brain oedema following ischaemia, or tumours, diarrhoea, hypertension (diuretic),
15 osteoporosis and glaucoma.

Suitable dosage range are 0.1-500 milligrams daily, and especially 10-70 milligrams daily, administered once or twice a day, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject
20 involved, and further the preference and experience of the physician or veterinarian in charge.

The following examples will illustrate the invention further, however, they are not to be construed as limiting.

Example 1

3-Trifluoromethylphenyl-4-bromo-2-(5-tetrazolyl)phenyl urea

25 3-Trifluoromethylphenyl isocyanate (0.41 mL, 3.0 mmol) and 5-(2-amino-5-bromophenyl)tetrazole (0.6g, 2.5 mmol) were added to toluene (10 mL). The reaction mixture was stirred at room temperature overnight. The precipitate was filtered and washed with toluene and then with petroleum ether to give 0.53g of the desired compound. M.p. 269-270 °C.

The following compounds were prepared analogously:

- 3-Trifluoromethylphenyl-2-(5-tetrazolyl)phenyl urea. M.p. 257-258 °C.
3-Trifluoromethylphenyl-2-(5-tetrazolyl)phenyl thiourea. M.p. >200 °C (dec.)
3-Trifluoromethylphenyl-4-phenyl-2-(5-tetrazolyl)phenyl urea. M.p. 260 °C.
4-Trifluoromethylphenyl-2-(5-tetrazolyl)phenyl urea. M.p. 240 °C (dec.).
3-Chlorophenyl-2-(5-tetrazolyl)phenyl urea. M.p. 243 °C (dec.).
Phenyl-2-(5-tetrazolyl)phenyl urea. M.p. 239 °C (dec.).
3-Trifluoromethylphenyl-4-nitro-2-(5-tetrazolyl)phenyl urea. M.p. 204-205 °C.
3-Trifluoromethylphenyl-4-(2-naphthyl)-2-(5-tetrazolyl)phenyl urea. M.p. 257-258 °C.
3-Trifluoromethylphenyl-4-(3-pyridyl)-2-(5-tetrazolyl)phenyl urea. M.p. 148-152 °C.
5 3-Trifluoromethylphenyl-4-(1-naphthyl)-2-(5-tetrazolyl)phenyl urea. M.p. 207-208 °C.
3-Trifluoromethylphenyl-4-(4-trifluoromethylphenyl)-2-(5-tetrazolyl)phenyl urea. M.p. 135-140 °C.
3-Trifluoromethylphenyl-4-(3-furyl)-2-(5-tetrazolyl)phenyl urea. M.p. 260-261 °C.
3-Trifluoromethylphenyl-4-(3-thienyl)-2-(5-tetrazolyl)phenyl urea. M.p. 259-260 °C.
10 3-Trifluoromethylphenyl-4-(3-nitrophenyl)-2-(5-tetrazolyl)phenyl urea. M.p. 135-140 °C.
3-Trifluoromethylphenyl-4-(4-ethoxycarbonylphenyl)-2-(5-tetrazolyl)phenyl urea. M.p. 262-263 °C.
3-Trifluoromethylphenyl-4-(4-diethylaminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea.
15 M.p. 264-264 °C.
3-Trifluoromethylphenyl-4-(4-aminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea. M.p. 252-253 °C.
3-Trifluoromethylphenyl-2-(4-hydroxy-1,2,4-triazol-3-yl)phenyl urea. M.p. 220-221 °C.
3-Trifluoromethylphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl urea. M.p. >300
20 °C.
3-Trifluoromethylphenyl-2-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl urea. M.p. >300 °C.
3-Trifluoromethylphenyl-4-biphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl urea. M.p. 166 °C.
3-Bromophenyl-4-bromo-2-(5-tetrazolyl)phenyl urea. M.p. 142 °C.

Example 2**5-(2-Aminophenyl)tetrazole**

2-Aminobenzonitrile (9.44 g, 80 mmol), sodium azide, (6.24 g, 0.1 mol), ammonium
5 chloride (5.12 g, 0.1 mol) and dimethylformamide (50 mL) were mixed and heated at
120 °C overnight. The solvent was evaporated and the residue taken up in water. The
crude product was isolated by filtration and re-crystallised from water. A yield of 8.4 g
of pure product was obtained

10 Analogously were made:

5-(2-Amino-5-bromophenyl)tetrazole

5-(4-Amino-3-biphenyl)tetrazole

5-(2-Amino-5-nitrophenyl)tetrazole

5-(2-Amino-4-(2-naphthyl)phenyl)tetrazole

15 5-(2-Amino-4-(3-pyridyl)phenyl)tetrazole

5-(2-Amino-4-(1-naphthyl)phenyl)tetrazole

5-(2-Amino-4-(4-trifluoromethylphenyl)phenyl)tetrazole

5-(2-Amino-4-(3-furyl)phenyl)tetrazole

5-(2-Amino-4-(3-thienyl)phenyl)tetrazole

20 5-(2-Amino-4-(4-trifluoromethylphenyl)phenyl)tetrazole

5-(2-Amino-4-(3-nitrophenyl)phenyl)tetrazole

5-(2-Amino-4-(4-ethoxycarbonylphenyl)phenyl)tetrazole

5-(2-Amino-4-(4-diethylaminocarbonylphenyl)phenyl)tetrazole

5-(2-Amino-4-(4-aminocarbonylphenyl)phenyl)tetrazole

25

Example 3**2-Amino-4-phenylbenzonitrile**

A mixture of 2-amino-5-bromobenzonitrile (1.0 g, 5 mmol), phenylboronic acid (0.92 g,
30 7.5 mmol), tetrakis(triphenylphosphine)palladium (50 mg) and potassium carbonate
(3.5 g, 25 mmol) in dimethoxyethane/water 2:1 (60 mL) was heated at reflux for 4
hours. After cooling to room temperature the reaction was diluted with water and

extracted with ethyl acetate. The organic phase was dried and solvent evaporated. Trituration with petroleum ether gave 0.89 g of the desired compound.

Similarly were made:

2-Amino-4-(2-naphthyl)benzonitrile

5 2-Amino-4-(3-pyridyl)benzonitrile

2-Amino-4-(1-naphthyl)benzonitrile

2-Amino-4-(4-trifluoromethylphenyl)benzonitrile

2-Amino-4-(3-furyl)benzonitrile

2-Amino-4-(3-thienyl)benzonitrile

10 2-Amino-4-(3-nitrophenyl)benzonitrile

2-Amino-4-(4-ethoxycarbonylphenyl)benzonitrile

2-Amino-4-(4-diethylaminocarbonylphenyl)benzonitrile

2-Amino-4-(4-aminocarbonylphenyl)benzonitrile

1-(3-Nitro-4-biphenyl)-1,2-dihydro-1,2,4-triazol-3-one

15

Example 4

3-Trifluoromethylphenyl-4-amino-2-(5-tetrazolyl)phenyl urea

A solution of 3-trifluoromethylphenyl-4-nitro-2-(5-tetrazolyl)phenyl urea (0.8g, 2.0
20 mmol) in 96% ethanol was hydrogenated over 5% palladium on charcoal for 3 hours at room temperature. The reaction mixture was filtered through a pad of celite and the solvent evaporated off to give 0.75 g of the desired product. M.p. 175-180 °C.

25

Example 5

3-Trifluoromethylphenyl-4-acetylamino-2-(5-tetrazolyl)phenyl urea

To a solution of 3-trifluoromethylphenyl-4-amino-2-(5-tetrazolyl)phenyl urea (0.22g, 0.6 mmol) in 17% aqueous sodium acetate (5 mL), cooled on an ice bath, was added
30 acetic anhydride (1 mL). The reaction was stirred at 0 °C for another hour. The precipitate was filtered off and re-crystallised from 96% ethanol to give 0.12g of the desired material. M.p. 280-282 °C.

Example 6**3-Trifluoromethylphenyl-4-benzoylamino-2-(5-tetrazolyl)phenyl urea**

To a solution of 3-trifluoromethylphenyl-4-amino-2-(5-tetrazolyl)phenyl urea (0.36g,
5 1.0 mmol) in tetrahydrofuran (40 mL) was added triethylamine (0.17 mL, 1.2 mmol).
The solution was cooled on an ice bath and benzoylchloride (0.14 mL, 1.2 mmol) was
added. The reaction was stirred at 0 °C for another 30 min. The reaction was poured
into water. The precipitate was filtered off and re-crystallised from 96% ethanol to give
0.28g of the desired material. M.p. 271-272 °C.

10

Example 7**4-Methylphenylboronic acid**

To a solution of 4-iodotoluene (35g, 160.5 mmol) in diethyl ether (400 mL) was added
15 n-butyllithium (2 M in pentane, 88.3 mL, 176.6 mmol) at 0 °C. After stirring at 0 °C for
another 15 min the solution was cooled to -60 °C and tributylborate (60.6 mL, 224.7
mmol) was added. The cooling bath was removed and the reaction allowed to heat up
to room temperature. The solution was acidified with hydrochloric acid (2 N, 280 mL)
and the organic phase separated off. The aqueous phase was extracted with diethyl
20 ether 2 x 125 mL). The combined organic phases were extracted with sodium
hydroxide (1 N, 5 x 50 mL). The combined aqueous extracts were acidified to give
18.6g of the desired material.

Example 8

25

4-Carboxyphenylboronic acid

To a solution of 4-methylphenylboronic acid (34g, 0.25 mol) in aqueous sodium
hydroxide (0.5 N, 1000 mL) was added potassium permanganate (83g, 0.53 mol)
while keeping the temperature at 35-40 °C. After the addition the reaction was filtered
30 and the filtrate acidified with concentrated hydrochloric acid (65 mL). The product was
filtered off. A yield of 29.6 g was obtained. M.p. 228 °C.

Example 9**4-Ethoxycarbonylphenylboronic acid**

A solution of 4-carboxyphenylboronic acid (15g, 0.09 mol), 99% ethanol (150 mL) and concentrated sulphuric acid (0.5 mL) was heated to reflux for two days. The volume was reduced to approximately 20 mL. The residue was triturated with petroleum ether to give 13.4 g of the desired material.

10

Example 10**4-Aminocarbonylphenylboronic acid**

A solution of 4-carboxyphenylboronic acid (10g, 0.06 mol) and thionyl chloride (875 mL) was heated to 50-60 °C overnight. The thionyl chloride was evaporated off. Half of the residue was added to concentrated ammonia (30 mL). The reaction was heated to reflux. Hot filtration and subsequent acidification of the filtrate yielded the crude material. The crude material was purified by suspending it in diluted sodium hydrogencarbonate to give 1.09 of the desired material.

20

Similarly was made;

4-Dimethylaminocarbonylphenylboronic acid

25

Example 11**3-Trifluoromethylphenyl-4-(4-carboxyphenyl)-2-(5-tetrazolyl)phenyl urea**

To a suspension of 3-trifluoromethylphenyl-4-(4-ethoxycarbonylphenyl)-2-(5-tetrazolyl)phenyl urea (4.5g, 9 mmol) in 96% ethanol was added sodium hydroxide (4 N, 25 mL). The reaction was heated to reflux for 30 min, then cooled to room temperature and acidified with hydrochloric acid. The precipitate was filtered off to give 3.8g of the desired material. M.p. 300 °C (dec.).

30

Example 12**3-Trifluoromethylphenyl-4-(4-anilinocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea**

A mixture of 3-trifluoromethylphenyl-4-(4-carboxyphenyl)-2-(5-tetrazolyl)phenyl urea
5 (1.9g, 4 mmol) and thionyl chloride (10 mL) was heated to 50 °C for 6 hours. The
excess of thionyl chloride was evaporated off. Diethyl ether was added to the residue
to give 2.2g of solid material. Half of this material was suspended in tetrahydrofuran.
Aniline (0.2 mL, 2.2 mmol) and triethylamine (0.5 mL, 3.6 mmol) were added. After
stirring for 30 min the solvent was evaporated off. The residue was suspended in
10 water and a small amount of diluted hydrochloric acid was added. The solid material
was filtered off and re-crystallised from 96% ethanol to give 0.2g of the desired
material. M.p. >300 °C.

Example 13

15

4-biphenyl-2-(5-tetrazolyl)phenyl urea

To a solution of N,N-carbonyldiimidazole (0.96g, 5.0 mmol) and imidazole (0.68g, 10
mmol) in tetrahydrofuran (10 mL) at 0 °C was added 4-aminobiphenyl (1.0g, 5.9
mmol) in tetrahydrofuran (10 mL). After stirring at 0 °C for 10 min 5-(2-
20 aminophenyl)tetrazole (1.14g, 7.1 mmol) was added. The reaction was stirred for
another 4 hours and filtered. The filtrate was evaporated to dryness and the crude
product purified by column chromatography. A yield of 0.28g was obtained. M.p. 224-
226 °C.

25 Similarly were made:

3-Biphenyl-2-(5-tetrazolyl)phenyl urea. M.p. 189-191 °C.

5-Indanyl-2-(5-tetrazolyl)phenyl urea. M.p. 154-157 °C.

3-Acetylphenyl-2-(5-tetrazolyl)phenyl urea. M.p. 115 °C.

3-Biphenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.

30 3-(3-Pyridyl)phenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.

Example 14

4-Hydroxy-3-(2-aminophenyl)-[1,2,4]triazole

A solution of 4-hydroxy-3-(2-nitrophenyl)-1,2,4-triazole (0.38g, 1.8 mmol), prepared according H.G.O. Becker in J. Prakt. Chem., 1970, 312, 610, in 96% ethanol was hydrogenated over 5% palladium on charcoal at room temperature for 1 hour. The
5 reaction was filtered through a pad of celite to give desired material on evaporation of the solvent.

Example 15**10 1-(4-Bromophenyl)-1,2-dihydro-[1,2,4]triazol-3-one**

A mixture of 4-bromophenylhydrazine hydrochloride (5.0g, 22.4 mmol) and urea (8.1g, 134 mmol) was heated to 80 °C overnight in 1-methyl-2-pyrrolidinone (25 mL). The reaction was poured into water (250 mL) and concentrated ammonia was added until basic pH. The solution was cooled on an ice bath and the semicarbazone filtered off.
15 The semicarbazone (1.0g, 4.4 mmol) was stirred in triethyl orthoformate (8 mL) at 90 °C for three days. The reaction mixture was cooled to room temperature and the crude material filtered off. Re-crystallisation from methanol afforded the desired product.

20

Example 16**1-(4-Bromo-2-aminophenyl)-1,2-dihydro-1,2,4-triazol-3-one**

To a solution of 1-(4-bromophenyl)-1,2-dihydro-[1,2,4]triazol-3-one (0.25g, 1.0 mmol)
25 in concentrated sulphuric acid (10 mL) at 0 °C was added potassium nitrate (0.13g, 1.2 mmol). The reaction was stirred for another hour at 0 °C and then at room temperature overnight. The reaction mixture was poured into water and the precipitate filtered off to give 0.28g of the desired nitro compound. The nitro compound (0.28g, 1.0 mmol) suspended in 96% ethanol was hydrogenated over 5% palladium on
30 charcoal to give the desired material.

Example 17

5-(2-aminophenyl)-3H-1,3,4-oxadiazol-2-one

A solution of 2-nitrobenzoylhydrazine (9.05g, 0.05 mol) in dioxane (30 mL) was slowly added to a solution of trichloromethyl chloroformate (4.6 mL, 0.04 mol) in dioxane (30 mL) at room temperature. On completion of the addition the reaction was heated to
5 reflux for 4 hours. The solvent was evaporated off and the residue re-crystallised from 96% ethanol (50 mL) to give 7.15 g of the 5-(2-nitrophenyl)-3H-[1,3,4]oxadiazol-2-one. M.p. 157-158 °C. A solution of the nitro compound (2g, 9.7 mmol) in 96% ethanol (25 mL) was hydrogenated over 5% palladium on charcoal to give desired
1.6g of the desired amine.

10


Example 18**1-(3-amino-4-biphenyl)-1,2-dihydro-1,2,4-triazol-3-one**

A solution of 1-(3-nitro-4-biphenyl)-1,2-dihydro-1,2,4-triazol-3-one in 96% ethanol
15 (25 mL) was hydrogenated over 5% palladium on charcoal to give the desired amine.

CLAIMS:

1. A compound having the formula

5



or a pharmaceutically acceptable salt thereof

- 10 wherein one of R¹, R² and R³ is a cyclic or heterocyclic acidic functional group having a pKa value below 8 or a group which is convertible in vivo to such a group;

- R⁴, R⁵ and the two other substituents R¹, R² and R³ are each independently selected from hydrogen; alkyl; alkoxy; hydroxy; halogen; trifluoromethyl; cyano; nitro; amino; alkylamino; -COOR⁷; -NHSO₂-alkyl; -SO₂N(R⁷)₂; -SO₂OR⁷; -CO-R⁷; aryl, biphenyl, phenylamino, phenoxy or heteroaryl, wherein the aryl, biphenyl, phenylamino, phenoxy or heteroaryl group may be substituted one or more times with substituents selected from alkyl, hydroxy, alkoxy, halogen, trifluoromethyl, cyano, nitro, amino and alkylamino; aryl and heteroaryl, or R³ and R⁴ or R⁴ and R⁵ together form a cyclic structure and the other substituents R¹, R², R³, R⁴ and R⁵ is as defined above;
- 20

and R⁷ is hydrogen, alkyl, amino or phenyl;

Y is -CO-, -CS-, -SO₂-, or -C(=N-R⁸)-, wherein R⁸ is hydrogen, alkyl, or cyano;

25

X is -NH-, -CH₂-NH-, or -SO₂-NH-;

Z is NR⁶, O, -CH=CH-, -N=CH-, or -CH=N-

- 30 R⁶ is hydrogen, or alkyl;

R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ are each independently selected from hydrogen; alkyl; alkoxy; hydroxy; halogen; trifluoromethyl; cyano; nitro; amino; alkylamino; -COOR⁷; -NHSO₂-alkyl; -SO₂N(R⁷)₂; -SO₂OR⁷; -CO-R⁷; aryl, biphenyl, phenylamino, phenoxy or heteroaryl, wherein the aryl, biphenyl, phenylamino, phenoxy or heteroaryl group may be substituted one or more times with substituents selected from alkyl, hydroxy, alkoxy, halogen, trifluoromethyl, cyano, nitro, amino and alkylamino; aryl and heteroaryl, or one of R¹¹ and R¹², R¹² and R¹³, R¹³ and R¹⁴ and R¹⁴ and R¹⁵ together form a cyclic structure and the other substituents R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ is as defined above and R⁷ is as defined above;

2. A compound according to claim 1 wherein one of R¹, R² and R³ is 3-hydroxy-4-oxo-pyranyl, 2-hydroxy-4-oxo-pyrimidyl, 4-hydroxy-1,2,4-triazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 2,4-dioxo-imidazolidinyl, 2,5-dioxo-3-hydroxy-pyrrolyl, 2,5-dioxo-pyrrolidinyl, 2,4-dioxo-1,3-thiazolidinyl, 3-hydroxy-isoxazolyl, 5-hydroxy-isoxazolyl, 3-hydroxy-isothiazolyl, 3-hydroxy-1,2,5-thiadiazolyl, tetrazolyl, 3-hydroxy-triazolyl, 3-hydroxy-pyrazolyl, 2-hydroxy-1,3,4-oxadiazolyl or 2-hydroxy-3,4-dioxo-cyclobutenyl, 3-oxo-1,2-dihydro-1,2,4-triazolyl, 2-oxo-3H-1,3,4-oxadiazolyl, 3-oxo-1,2-dihydro-1,2,4-triazolyl; Z is NR⁶ and Y is CO;

20

3. A compound of claim 1, said compound being:

- 3-Trifluoromethylphenyl-4-nitro-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(2-naphthyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-pyridyl)-2-(5-tetrazolyl)phenyl urea;
- 25 3-Trifluoromethylphenyl-4-(1-naphthyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-trifluoromethylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-furyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-thienyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(3-nitrophenyl)-2-(5-tetrazolyl)phenyl urea;
- 30 3-Trifluoromethylphenyl-4-(4-ethoxycarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-diethylaminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-4-(4-aminocarbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
- 3-Trifluoromethylphenyl-2-(4-hydroxy-1,2,4-triazol-3-yl)phenyl urea;

- 3-Trifluoromethylphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl urea;.
3-Trifluoromethylphenyl-2-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl urea;
3-Trifluoromethylphenyl-4-biphenyl-2-(3-oxo-1,2-dihydro-1,2,4-triazol-1-yl)phenyl
urea;
5 3-Trifluoromethylphenyl-4-amino-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-acetylamino-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-benzoylamino-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-(4-carboxyphenyl)-2-(5-tetrazolyl)phenyl urea;
3-Trifluoromethylphenyl-4-(4-anilino-carbonylphenyl)-2-(5-tetrazolyl)phenyl urea;
10 4-Biphenyl-2-(5-tetrazolyl)phenyl urea;
3-Biphenyl-2-(5-tetrazolyl)phenyl urea;
5-Indanyl-2-(5-tetrazolyl)phenyl urea;
3-Bromophenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.
3-Acetylphenyl-2-(5-tetrazolyl)phenyl urea.
15 3-Biphenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.
3-(3-Pyridyl)phenyl-4-bromo-2-(5-tetrazolyl)phenyl urea.

4. A pharmaceutical composition comprising a therapeutically effective
amount of a compound of any of the claims 1 to 3 or a pharmaceutically acceptable
20 salt thereof together with at least one pharmaceutically acceptable carrier or diluent.

5. The use of a compound according to claims 1 to 3 for the preparation of a
medicament for the treatment of a disorder or disease of a living animal body,
including a human, which disorder or disease is responsive to the blockade of chloride
25 channels.

6. The use of a compound according to claim 1 for the preparation of a
medicament for the treatment of sickle-cell anaemia, brain oedema following
ischaemia, or tumours, diarrhoea, hypertension (diuretic), osteoporosis, glaucoma,
30 allergic or inflammatory conditions or ulcers.

7. A method for the treatment of a disorder or disease of a living animal body,
including a human, which disorder or disease is responsive to the blockade of chloride


channels, comprising administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claims 1 to 3.

8. A method for the treatment of a disorder or disease of a living animal body which disorder or disease is sickle-cell anaemia, brain oedema following ischaemia, or tumours, diarrhoea, hypertension (diuretic), osteoporosis, glaucoma, allergic or inflammatory conditions or ulcers comprising administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound according to claims 1 to 3.

10


9. A method for the preparation of a compound of claims 1 to 3, comprising:

- a) reacting a compound having the formula



15

wherein W is O, or S and R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ is as defined above, with a compound having the formula




20

wherein R¹, R², R³, R⁴, R⁵ and R⁶ is as defined above, or

- b) reacting a compound having the formula


25

30



wherein X, Y, R⁶, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ is as defined above, with a compound...
having the formula

5



wherein Hal is halogen and R¹, R², R³, R⁴ and R⁵ is as defined above,

10

whereafter optionally the compound obtained is converted to another compound of the invention and/or a pharmaceutically acceptable salt thereof is formed using conventional methods.

- 15 10. The use of chloride channel blockers in the treatment of sickle cell anaemia.

INTERNATIONAL SEARCH REPORT

National Application No
PCT/DK- 98/00162

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D257/04 C07D249/12 C07D271/10 C07D401/10 C07D405/10 C07D409/10 A61K31/41		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 22807 A (NEUROSEARCH A/S) 13 October 1994 see claims ---	1-10
A	US 5 362 744 A (C.F. PURCHASE, JR. ET AL.) 8 November 1994 see claims ---	1-10
P, A	WO 97 45400 A (NEUROSEARCH A/S) 4 December 1997 see claims ---	1-10
P, A	WO 97 45111 A (NEUROSEARCH A/S) 4 December 1997 see claims -----	1-10
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
10 August 1998	18/08/1998	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center;">Chouly, J</div>	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/ 00162

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7,8,10
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7,8,10
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 98/00162

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9422807	A	13-10-1994	AU 683654 B	20-11-1997
			AU 6537894 A	24-10-1994
			CA 2160128 A	13-10-1994
			EP 0693053 A	24-01-1996
			FI 954746 A	17-11-1995
			JP 8510448 T	05-11-1996
			NO 953956 A	07-12-1995
			US 5696138 A	09-12-1997
US 5362744	A	08-11-1994	AU 1043795 A	13-06-1995
			WO 9514679 A	01-06-1995
WO 9745400	A	04-12-1997	AU 2962197 A	05-01-1998
			AU 2962297 A	05-01-1998
			WO 9745111 A	04-12-1997
WO 9745111	A	04-12-1997	AU 2962197 A	05-01-1998
			AU 2962297 A	05-01-1998
			WO 9745400 A	04-12-1997